186 related articles for article (PubMed ID: 27026382)
1. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma.
Qu Y; Zhao R; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Mar; 6():23594. PubMed ID: 27026382
[TBL] [Abstract][Full Text] [Related]
2. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
4. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
5. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
6. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Chang K; Qu Y; Dai B; Zhao JY; Gan H; Shi G; Zhu Y; Shen Y; Zhu Y; Zhang H; Ye D
Sci Rep; 2017 May; 7(1):2074. PubMed ID: 28522811
[TBL] [Abstract][Full Text] [Related]
8. Xp11 translocation renal cell carcinoma morphologically mimicking clear cell-papillary renal cell carcinoma in an adult patient: report of a case expanding the morphologic spectrum of Xp11 translocation renal cell carcinomas.
Parihar A; Tickoo SK; Kumar S; Arora VK
Int J Surg Pathol; 2015 May; 23(3):234-7. PubMed ID: 25519951
[TBL] [Abstract][Full Text] [Related]
9. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
[TBL] [Abstract][Full Text] [Related]
10. Levels of 4EBP1/eIF4E Activation in Renal Cell Carcinoma Could Differentially Predict Its Early and Late Recurrence.
Ichiyanagi O; Naito S; Ito H; Kabasawa T; Narisawa T; Kanno H; Kurota Y; Kurokawa M; Fukuhara H; Sakurai T; Nishida H; Kato T; Yamakawa M; Tsuchiya N
Clin Genitourin Cancer; 2018 Oct; 16(5):e1029-e1058. PubMed ID: 30297141
[TBL] [Abstract][Full Text] [Related]
11. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
13. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.
Argani P; Olgac S; Tickoo SK; Goldfischer M; Moch H; Chan DY; Eble JN; Bonsib SM; Jimeno M; Lloreta J; Billis A; Hicks J; De Marzo AM; Reuter VE; Ladanyi M
Am J Surg Pathol; 2007 Aug; 31(8):1149-60. PubMed ID: 17667536
[TBL] [Abstract][Full Text] [Related]
14. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.
Klatte T; Streubel B; Wrba F; Remzi M; Krammer B; de Martino M; Waldert M; Marberger M; Susani M; Haitel A
Am J Clin Pathol; 2012 May; 137(5):761-8. PubMed ID: 22523215
[TBL] [Abstract][Full Text] [Related]
16. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Med Oncol; 2014 Jan; 31(1):792. PubMed ID: 24307346
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.
Wu Y; Chen S; Zhang M; Liu K; Jing J; Pan K; Zhang L; Xu B; Lu X; Chen M
Pathol Oncol Res; 2021; 27():610360. PubMed ID: 34257577
[No Abstract] [Full Text] [Related]
18. Xp11.2 translocation renal cell carcinomas in young adults.
Xu L; Yang R; Gan W; Chen X; Qiu X; Fu K; Huang J; Zhu G; Guo H
BMC Urol; 2015 Jul; 15():57. PubMed ID: 26126525
[TBL] [Abstract][Full Text] [Related]
19. Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
Ma W; Yang J; Liu N; Pu X; Qu F; Xu L; Zhao X; Li X; Zhang G; Guo H; Li D; Gan W
BMC Cancer; 2020 Dec; 20(1):1182. PubMed ID: 33267784
[TBL] [Abstract][Full Text] [Related]
20. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
